Drugs / NM-101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06934941 | Nov 2024 → Oct 2025 overdue | — | Neuramedy Co. Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT05790382 | May 2023 → May 2024 | Parkinson disease | Neuramedy Co. Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NM-101 | “NM-101 is an anti-TLR2 antibody which may have clinical efficacy in Parkinson's disease patients.” NCT05790382 ↗1“a monoclonal antibody, NM-101” NCT06934941 ↗ |
| Modality | Protein / enzyme biologic | “NM-101 is an anti-TLR2 antibody” NCT05790382 ↗ |
| Route | Intravenous | “Ascending doses of NM-101. IV infusion over 2 hours” NCT05790382 ↗ |
| Target | TLR2 | “NM-101 is an anti-TLR2 antibody” NCT05790382 ↗ |